Author name: DrugPatentWatch

To identify Key Starting Materials (KSMs) for Active Pharmaceutical Ingredients (APIs), pharmaceutical companies and regulatory bodies follow a systematic approach […]

The generic drug market has been significantly impacted by the COVID-19 pandemic, with both challenges and opportunities arising from the

In the high-stakes world of pharmaceuticals, generic drugs have become the unsung heroes of healthcare accessibility. These cost-effective alternatives to

In the high-stakes world of pharmaceutical innovation, drafting detailed drug patent claims is a critical process that can make or

In the ever-evolving world of pharmaceuticals, a controversial practice has emerged that’s causing quite a stir: biologic product hopping. But

Enantiomer Switching: A Pharmaceutical Strategy to Extend Drug Patents Enantiomer switching, also known as chiral switching, is a strategy employed

In the rapidly evolving landscape of biosimilars, intellectual property (IP) strategy is paramount. Biosimilar manufacturers face unique challenges, including navigating

Introduction The Patent Trial and Appeal Board (PTAB) is a crucial component of the United States Patent and Trademark Office

Transitioning to a new Contract Development and Manufacturing Organization (CDMO) can be a complex and challenging process. However, by following